Skip to main content
. 2021 Apr 3;13(7):9243–9252. doi: 10.18632/aging.202838

Table 2. The general characteristics of 67 critical COVID-19 patients by CRRT.

Variable Total CRRT (n=38) Non-CRRT (n=29) t/χ2/Z P
Age (years) 67.6±12.3 66.9±11.8 68.6±13.0 0.552a 0.583
Sex
Female 16 7(18.4) 9(31.0) 1.440c2 0.230
Male 51 31(81.6) 20(69.0)
Smoking 8 6(21.4) 2(8.7) 0.269f
Clinical outcomes
Cure/Improve 22 7(18.9) 15(51.7) 7.873c2 0.005
Death 44 30(81.1) 14(48.3)
Underlying conditions
Diabetes 14 7(18.4) 7(24.1) 0.325c2 0.568
Hypertension 37 19(50.0) 18(62.1) 0.969c2 0.325
Tumor 5 2(5.3) 3(10.3) 0.645f
COPD 1 0(0.0) 1(3.4) 0.433f
Hospitalization time (days) 23.3±16.6 23.6±15.6* 23.0±18.1 477.5b 0.449
Laboratory test results
SO2 (%) 92.5(85,95) 90(84.5,95)* 93(88,95.5)* 462.5b 0.343
PLT (109/L) 153(105.5,212.5) 127(98.25,179) 185(112,247) 731.0b 0.023
WBC count (109/L) 9.9±4.4 9.8±3.9 10.0±4.9 0.180a 0.858
Neutrophil count (109/L) 8.80±4.30 8.80±3.89 8.80±4.87 -0.003a 0.997
Neutrophil % 89.9(80.1,92.1) 89.95(86.6,93.13)* 89.8(78.5,91.4) 420.5b 0.321
Lymphocyte count (109/L) 0.59(0.42,0.96) 0.55(0.39,0.72) 0.64(0.48,1.12) 666.5b 0.146
Albumin (g/L) 29.88±5.51 28.68±4.79 31.44±6.06 2.080a 0.041
LDH (U/L) 434(328.5,592) 472(339.25,661) 430(321,502) 451.0b 0.208
Maximum creatinine value during hospitalization (μmol/L) 146(92.45,291.35) 198.85(123.62,340.95) 132.7(63.1,214) 364.0b 0.018
High-sensitivity troponin I 36(14.6,140.5) 46.6(19.9,184.25)* 23.7(12.55,70.82)* 354.0b 0.229
D-dimer (ug/mL) 3.31(0.88,8) 2.26(0.92,8)* 3.53(0.88,6.98) 513.5b 0.915
CRP (mg/L) 96.7(43.8,143.8) 97.76(54.34,143.57)* 89.16(33.93,143.8) 480.0b 0.583
Ferritins (μg/L) 1614(837,20000) 1618.59(907.86,2000)* 1447.99(851.62,2000)* 183.0b 0.522
PCT (ng/mL) 0.24(0.12,0.41) 0.3(0.14,0.49)* 0.23(0.12,0.27)* 276.5b 0.120
Maximum IL-6 (pg/mL)
<P25 (<=250) 15 11(28.9) 4(13.8) 4.438c2 0.109
P25~P75 (250 -4000) 32 14(36.8) 18(62.1)
>=P75(>=4000) 20 13(34.2) 7(24.1)
Lung CT main performance Ground glass 29 12(35.3) 17(65.4) 5.342c2 0.021
Consolidation 31 22(64.7) 9(34.6)
Treatments
Antiviral 64 35(97.2) 29(100.0) 1.000f
Tracheal cannula 56 34(100.0) 22(75.9) 0.003f
Tracheotomy 13 8(24.2) 5(17.9) 0.368c2 0.544
Antibiotic 62 35(97.2) 27(96.4) 1.000f
Hormone 47 30(83.3) 17(70.8) 1.326c2 0.250
Globulin 38 24(77.4) 14(56.0) 2.911c2 0.088
ACEI/ARB 4 1(3.3) 3(13.6) 0.299f
Convalescent plasma 10 7(21.2) 3(11.1) 0.485c1 0.486
Traditional Chinese medicine and pharmacy 18 8(25.8) 10(41.7) 1.546c2 0.214
High flow nasal catheter oxygen inhalation 49 25(75.8) 24(85.7) 0.950c2 0.330
Non-invasive ventilation 40 23(65.7) 17(65.4) 0.001c2 0.979
Invasive mechanical ventilation 59 37(100.0) 22(75.9) 0.002f
ECMO 9 6(17.1) 3(10.7) 0.131c1 0.717
Complications
AKI 49 30(81.1) 19(65.5) 2.059c2 0.151
Respiratory failure 57 35(94.6) 22(88.0) 0.385f
Gastrointestinal bleeding 25 16(48.5) 9(40.9) 0.306c2 0.580
Acute liver dysfunction 41 26(81.2) 15(83.3) 0.000c1 1.000
Acute myocardial injury 56 32(88.9) 24(88.9) 1.000f
ARDS 35 25(71.4) 10(47.6) 3.175c2 0.075
MODS 30 26(81.2) 4(25.0) 14.400c2 <0.001

Note: a: t value by t test; b: Z value by Wilcoxon rank sum test; c1: continuity corrected χ2 value by χ2 test; c2: χ2 value by χ2 test; f: Fisher exact probability test p value.

*: contains missing values.

PLT: Blood platelets; WBC count: White blood cell count; SO2: Blood oxygen saturation; LDH: Lactate dehydrogenase; CRP: C-reactive protein; PCT: Procalcitonin; IL6: Interleukin 6; COPD: Chronic obstructive pulmonary disease; AKI: acute kidney injury.